Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
Expert Opin Investig Drugs. 2012 Feb;21(2):227-33. doi: 10.1517/13543784.2012.651125. Epub 2012 Jan 10.
MDV3100 is a rationally designed androgen receptor antagonist, which has recently been shown to improve survival in men with metastatic castration-resistant prostate cancer previously treated with docetaxel chemotherapy. Drug development for advanced prostate cancer is advancing at a rapid pace with four other novel therapies (abiraterone, cabazitaxel, alpharadin and sipuleucel-T) also shown to improve overall survival in large randomised studies.
This review will cover the historical background of androgen deprivation therapy, recently approved agents for advanced prostate cancer, an overview of the clinical development of MDV3100 and an analysis of how MDV3100 may fit into future treatment protocols for this disease.
Full analysis of safety and efficacy data is awaited; however, MDV3100 appears to be a well-tolerated addition to the expanding portfolio of effective drugs for the treatment of advanced prostate cancer.
MDV3100 是一种经过合理设计的雄激素受体拮抗剂，最近的研究表明，它可改善先前接受多西紫杉醇化疗的转移性去势抵抗性前列腺癌男性患者的生存。随着另外四种新型疗法（阿比特龙、卡巴他赛、镭 223 及 sipuleucel-T）也在大型随机研究中显示可改善总生存期，晚期前列腺癌的药物研发正在迅速推进。
这篇综述将涵盖雄激素剥夺疗法的历史背景、最近批准用于晚期前列腺癌的药物、MDV3100 的临床开发概述以及分析 MDV3100 如何适用于该疾病未来的治疗方案。
尚待充分分析安全性和疗效数据；然而，MDV3100 似乎是一种耐受性良好的药物，可添加到不断扩大的治疗晚期前列腺癌的有效药物组合中。
